BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has a strategic collaboration with Shoreline Biosciences, Inc. to develop and commercialize a portfolio of NK-based cell therapeutics. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
IPO Year: 2016
Exchange: NASDAQ
Website: beigene.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2024 | $300.00 | Overweight | Morgan Stanley |
| 9/18/2024 | $288.00 | Mkt Outperform | JMP Securities |
| 2/6/2024 | $185.00 | Overweight | JP Morgan |
| 9/12/2023 | $259.00 | Outperform | Macquarie |
| 8/17/2023 | $287.00 | Buy | Jefferies |
| 7/17/2023 | $275.00 | Buy | Citigroup |
| 6/30/2023 | $335.00 → $196.00 | Outperform → Mkt Perform | Bernstein |
| 1/12/2023 | $308.00 | Buy | Daiwa Securities |
| 10/13/2022 | $205.00 | Neutral → Buy | Guggenheim |
| 10/13/2022 | $177.00 → $200.00 | Mkt Perform → Outperform | SVB Leerink |